Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
100%
Randomized Double-blind
100%
Ritonavir-boosted Darunavir
100%
Non-inferiority
100%
Doravirine
100%
Antiretroviral Naïve
100%
Phase II Trial
100%
Adverse Events
45%
MRNA Abundance
36%
One Dose
27%
Darunavir
27%
HIV RNA
18%
HIV Viral Load
18%
Efficacy Endpoint
18%
Nucleoside Reverse Transcriptase Inhibitors
18%
Time to Discontinuation
18%
Antiretroviral Therapy
9%
Upper Respiratory Tract Infection
9%
Nausea
9%
Treatment Group
9%
Long-term Treatment
9%
Accruals
9%
Lipid Profile
9%
Between-group
9%
HIV-1 Infection
9%
Clinical Centers
9%
LDL Cholesterol
9%
U.S. Food
9%
Serum Lipids
9%
Abacavir
9%
Ritonavir
9%
Emtricitabine
9%
Headache
9%
Treatment Difference
9%
Diarrhea
9%
Change from Baseline
9%
Merck
9%
Response System
9%
Previously Untreated
9%
Interactive Web Response
9%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
9%
Voice User Interface
9%
Lamivudine
9%
Phase II Study
9%
Baseline Characteristics
9%
Treatment Emergent
9%
Tenofovir Disoproxil Fumarate
9%
Non-high-density Lipoprotein Cholesterol (non-HDL-C)
9%
Inhibitor Therapy
9%
Treatment-naïve
9%
Treatment Assignment
9%
SNaPshot Method
9%
Safety Endpoints
9%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Ritonavir
100%
Darunavir
100%
Doravirine
100%
Adverse Event
45%
Drug Therapy
18%
Reverse-Transcriptase Inhibitor
18%
High Density Lipoprotein Cholesterol
9%
Low Density Lipoprotein Cholesterol
9%
Abacavir
9%
Headache
9%
Diarrhea
9%
Human Immunodeficiency Virus 1 Infection
9%
Nausea
9%
Nonnucleoside Reverse Transcriptase Inhibitor
9%
Emtricitabine
9%
Lamivudine
9%
Acivicin
9%
Antiretroviral Therapy
9%
Upper Respiratory Tract Infection
9%
Tenofovir Disoproxil
9%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Ritonavir
100%
Darunavir
100%
Doravirine
100%
Adverse Event
45%
RNA Directed DNA Polymerase Inhibitor
18%
Upper Respiratory Tract Infection
9%
Headache
9%
Nausea
9%
High Density Lipoprotein Cholesterol
9%
Low Density Lipoprotein Cholesterol
9%
Human Immunodeficiency Virus 1 Infection
9%
Abacavir
9%
Emtricitabine
9%
Diarrhea
9%
Acivicin
9%
Nonnucleoside Reverse Transcriptase Inhibitor
9%
Lamivudine
9%
Tenofovir Disoproxil
9%
Neuroscience
Human Immunodeficiency Virus
100%
Ritonavir
100%
Darunavir
100%
Reverse-Transcriptase Inhibitor
20%
Blood Plasma
20%
Low Density Lipoprotein Cholesterol
10%
High Density Lipoprotein Cholesterol
10%
Emtricitabine
10%
Abacavir
10%
Headache
10%
Non-Nucleoside Reverse Transcriptase Inhibitors
10%
Tenofovir Disoproxil
10%
Lamivudine
10%
Upper Respiratory Tract
10%